TITLE

PHARMAGENESIS JOINT VENTURE TO MAKE/SELL PG2 IN CHINA

PUB. DATE
July 2001
SOURCE
Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the joint venture forged by Pharmagenesis Inc. in Palo Alto, California, with Tianjin Zhong Xin Pharmaceutical Group company in China to manufacture and market the cancer therapy drug PG2 developed by Pharmagenesis in China.
ACCESSION #
4764380

 

Related Articles

  • PHARMAGENESIS APPROVED TO SELL FERIDEX IN CHINA.  // Worldwide Biotech;Apr2001, Vol. 13 Issue 4, p1 

    Reports on the approval received by Pharmagenesis Inc. from the Chinese State Drug Administration to market and sell Feridex, a magnetic resonance imaging contrast agent designed for the early detection of liver lesions, in China.

  • CHINA CERTIFIES PHARMAGENESIS' BONE MARROW STIMULANT PG2.  // Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p1 

    Reports on a drug certificate awarded by China's State Drug Administration to Pharmagenesis Inc. for its plant-derived hematopoiesis enhancer PG2.

  • Eli Lilly and Pharmagenesis agree to research antifungals from plants.  // Chemical Market Reporter;11/11/96, Vol. 250 Issue 20, p19 

    Reports on the collaboration of Pharmagenesis Inc. and Eli Lilly and Co. to isolate and develop antifungal agents derived from microorganisms associated with plants known to be resistant to fungal infections.

  • PIERRE FABRE LICENSES PHARMAGENESIS ANTI-CANCER HERBAL DRUG.  // Worldwide Biotech;May2003, Vol. 15 Issue 5, p5 

    Reports that research and development company, Pharmagenesis Inc. has signed an agreement with Pierre Fabre Medicament to license PG490-88Na, a patented derivative of a compound from a plant widely used in Chinese medicine.

  • From Europe to China--a new focus. Wechsler, Jill // Pharmaceutical Executive;Sep97, Vol. 17 Issue 9, p20 

    Focuses on the pharmaceutical industry in the People's Republic of China. Signing of the Mutual Recognition Agreement on pharmaceutical plant inspection between the United States and Europe; Upgrading of domestic pharmaceutical capabilities in the country; Difficulty of drug distribution in the...

  • Homeopathic drugs naturally want spot in mainstream market. Magiera, Marcy; Colford, Steven W. // Advertising Age;8/31/92, Vol. 63 Issue 35, p3 

    Reports that marketers of homeopathic medicines want to write a prescription for the American mainstream and they are spending marketing dollars doing it. Remedies that treat an ailment with small doses of natural substances; Commonly available in Europe; Homeopathic marketers expect that to...

  • New drugs often not that new.  // Aging;1991, Issue 362, p44 

    Reports on a study by the Senate Special Committee on Aging that found the vast majority of new pharmaceuticals placed on the market have little or no advantage over the usually less expensive drug therapies.

  • Pharmaceutical companies.  // Business News New Jersey;1998 Book of Lists, Vol. 11, p100 

    Ranks pharmaceutical companies in New Jersey by number of employees in their payroll. Includes Johnson & Johnson; Merck & Co.; Bristol-Myers Squibb; Schering-Plough; Novartis Pharmaceuticals.

  • Merger of the medicines. Nadeau, Jean Benoit; Dionisi, Sandra // CA Magazine;Jan/Feb96, Vol. 129 Issue 1, p24 

    Discusses the impact of the changes in the health care system on the pharmaceutical industry in Canada. Increase in research and development spending; Formation of alliances or merger with other pharmaceutical or biotech companies as a means for pharmaceuticals to sustain their market share;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics